Thelma before Stem Cell Therapy From:krazykp12Views:2 0ratingsTime:01:33More inPeople Blogs Go here to read the rest: Thelma before Stem Cell Therapy - Video … Continue reading →

NEW YORK (AP) Shares of biotechnology company Pluristem Therapeutics Inc. bounced back Friday after the company responded to a report that a patient treated with its PLX stem cell therapy had died. THE SPARK: Bloomberg BusinessWeek reported Thursday that Pluristem did not disclose the death of a young patient who had been treated with its placental cell therapy before a $32 million public stock sale in September. Shares of Pluristem fell 23 percent Thursday. The Israeli company said Thursday evening that parts of the article were inaccurate or misleading. It said the patient, a Romanian girl whose name has not been disclosed, was "in imminent danger of death" at the time she was treated with the stem cells. She was not part of an organized clinical trial and was treated on a compassionate basis because no therapy options remained. Pluristem said the patient lived for six months after her treatment. She returned to Romania four months before she died and the company was not monitoring her health. Pluristem said it was not aware of her death at the time it sold the additional stock. Bloomberg said the patient died Sept. 12, the day the stock sale was announced. The sale … Continue reading →

Published on 10 November 2012 Hits: 77 Written by Jovee Marie N. Dela Cruz The Department of Health (DOH) on Friday said that it has become necessary to issue regulations for stem cell therapy in the country. Health Secretary Enrique Ona said that guidelines for clinics offering stem cell therapy will be released immediately by the DOH and the Food and Drug Administration. We will issue guidelines because here in the country we dont know where the stem cell offered by clinics come from, he said. According to the DOH, stem cell therapy belongs to the category of advanced cell therapy, which includes biologics and blood. Many countries apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy. In many countries, stem cell is considered an investigational intervention, Ona said. The DOH said that stem cell research employs both autologous (from same person) or allogenic (from another organism like an animal or another human cell or tissue sample) method. Ona said that because there are many steps in the preparation of this lab and invasive procedure, there is a need to have a regulatory framework to protect Filipino citizens. Link: DOH to regulate stem cell … Continue reading →

cryo cell | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health http://www.cordbloodrecommendation.com They were first used to regenerate healthy blood and immune cells for cancer patients. The treatment that has to be provided for leukemia should be such, that it would increase the amount of White Blood cells in the blood stream. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. This procedure can likewise diagnose disorders like malformations of fetus, fetal infection such as toxoplasmosis or rubella, fetal platelet count inside mum, fetal anaemia, and isoimmunisation to name a few. To make a long story short, the Adult Stem Cells did the trick. If the amount is less, the collected cord blood is used for scientific researches. Within an hour of receiving the stem cell treatment, she was able to turn her head and partially lift her arms. If there is any complication during delivery, the entire idea is abandoned. It is always wise to preserve this waste blood of the baby which is otherwise thrown … Continue reading →

Judi's November 8, 2012 Update Adult Stem Cell Treatment Update for Multiple Sclerosis, November 8, 2012From:judilecoqViews:5 0ratingsTime:05:29More inPeople Blogs Original post: Judi's November 8, 2012 Update - Video … Continue reading →

Pluristem Therapeutics is taking heat for its failure to disclose the death of a child treated on a compassionate use basis with its experimental placental stem cell treatment. Paul Knoepfler, a stem cell scientist and prolific stemblogger, bluntly criticizes Pluristem for what a bioethicist he interviewed called "science-by-press-release" in touting the apparent benefit of the treatment as life-saving, but failing to follow up. In its defense, Israel-based Pluristem said it didn't know that the child had died until later, because the doctor and family didn't tell the company. Its statement also said Pluristem maintains a culture of transparency. And indications were that the treatment had improved the child's physical condition. The bioethicist, associate professor Leigh Turner of the University of Minnesota Center for Bioethics, told Knoepfler that wasn't a good excuse: "Transparency is important, but it appears that the company is being transparent about dramatic improvements in health of individuals receiving Pluristems PLX Cells while failing to issue press release disclosing case of a child who died after undergoing this experimental intervention." In other words, if you're going to mention something favorable to your product, it's only ethical to mention the unfavorable. Once Pluristem had given favorable coverage to this … Continue reading →

CARLSBAD, CA--(Marketwire - Nov 9, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company focused on therapeutic and research products, today announced financial results for the three months ended September 30, 2012. Three Months Ended September 30, 2012 Revenue for the three months ended September 30, 2012 totaled $1.19 million compared to $0.84 million for the same period in 2011.Sales for Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 46% and 37%, respectively. LSC and LCT accounted for 44% and 56% of total revenue in the three months ended September 30, 2012 compared to 43% and 57%, respectively, for the same period of 2011. Research and development (R&D) expenses were $0.90 million for the three months ended September 30, 2012, compared to $1.13 million for the same period in 2011. The decrease was due primarily to lower stock-based compensation expense, lower personnel-related spending and lower consulting expenses, partially offset by higher stem cell line research and testing expenses and higher laboratory expenses associated with our Parkinson's disease program. The Company continues to invest in its sales and marketing infrastructure. Marketing expenses for the three months ended … Continue reading →